Navigation Links
Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
Date:7/10/2013

(PRWEB) July 10, 2013

On July 25 a judicial panel will consider the consolidation of federal Byetta, Januvia and Victoza lawsuits for pretrial purposes, according to court documents in In RE: Incretin Mimetics Products Liability Litigation (MDL-2452; U.S. Judicial Panel on Multidistrict Litigation). The Rottenstein Law Group LLP, a law firm that represents clients in Byetta, Victoza and Januvia lawsuits, explains the importance of this decision.

The three drugs each are designed to treat type-2 diabetes. The plaintiffs in the cases for the drugs all have common cause for suit, alleging that they suffered the same potentially dangerous side effects, according to court documents.

A March 2013 announcement* by the U.S. Food and Drug Administration mentioned findings similar to the allegations of the plaintiffs: That the drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas. Bristol-Myers Squibb subsidiary Amylin Pharmaceuticals makes Byetta, Merck Januvia and Novo Nordisk Victoza. Byetta and Januvia were also found to potentially increase the risk of thyroid cancer, according to the FDA, though the drugs’ labels did not notify patients of this alleged adverse side effect.**

“A multidistrict consolidation of the lawsuits involving the three drugs would benefit the plaintiffs because it could potentially improve efficiency in time-consuming, costly proceedings such as discovery,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “It reduces, or even eliminates, duplication of efforts.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged adverse side effects of Byetta, Januvia and Victoza to visit its FAQ page for quick answers to their questions about the drugs, their side effects and lawsuits. If there are additional questions, those looking for more information can use the contact form to get in touch with an attorney.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/januvia-lawsuits/pancreatic-cancer/prweb10913120.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuances of First Pretrial Order in Federal Stryker Hip Recall Litigation
2. ATA Hosts DC Summit on Federal Telemedicine and mHealth Policy
3. Bernstein Liebhard LLP Notes Plaintiffs’ Opposition to Defense Motion in Federal Litigation of DePuy Pinnacle Lawsuit Claims
4. Employers Are Choosing Orriant to Lower Overall Employee Healthcare Costs and Benefit from Federal Wellness Program Incentives
5. Mirena IUD Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Case Management Conference in Federal Mirena Side Effects Litigation
6. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
7. Federal Data Services Hub Does Exist, AISHealth.com Blog Post Reports
8. New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations
9. Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation
10. Federal Bar Association Chooses Marketing General Incorporated To Manage Mailing Lists
11. Biomet Hip Lawsuits Mount in Federal Biomet M2a Magnum Hip Replacement Litigation, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the University of California Berkeley, and other leading institutions in announcing the launch ... of institutions to change the way animals are raised for food. , Founding ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: